GPs turning the tide of hepatitis C
The good news is effective treatment is available and the range of options has increased.
In February, Federal Health Minister Tanya Plibersek ann-ounced the listing on the Pharmaceutical Benefits Scheme of two new protease inhibitors (telaprevir and boceprevir) for treatment of chronic hepatitis C genotype 1. These medications, and others expected to be released soon, have the capacity to turn the tide of hepatitis C-related deaths if we can optimise community awareness and treatment access. There are important roles for GPs in making this